ZILUCOPLAN

Zilucoplan 32.4 mg/0.81 mL injection, 28 x 0.81 mL syringes

ZILUCOPLAN (15325N)

Zilucoplan 32.4 mg/0.81 mL injection, 28 x 0.81 mL syringes
15325N
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Bridging therapy for generalised myasthenia gravis (gMG)

Restriction

Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Initial treatment - Treatment refractory gMG patients

Restriction

Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Continuing treatment - Treatment refractory gMG patients

Restriction

Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Transitioning from non-PBS to PBS-subsidised treatment - Grandfathering treatment - Treatment refractory gMG patients
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 28 # of repeats: 5 DPMQ: $41,658.62 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Zilbrysq